Codexis, based in Redwood City, California, USA, has been listed on NASDAQ since April 2009. Xeraya, through MLSCF, invested in Codexis in November 2007.
Codexis developed a biocatalytic chemical processes that can reduce manufacturing costs across a broad range of industries. The company’s proprietary technology enables novel solutions for cost-effective, efficient and environmentally sound production of pharmaceuticals, transportation fuels, and industrial chemicals.
Codexis’ focus is on improving R&D productivity for its partners while significantly reducing their capital expenditures and cost-of-goods using green chemistry methods – the design of chemical products and processes that reduce or eliminate the use and generation of hazardous substances.
John J. Nichols is CEO. Before Codexis, he spent more than 22 years in various capacities at Albemarle Corporation, a public company focused on the development, manufacture, and marketing of highly engineered specialty chemicals. Most recently, he was Senior Vice President, Strategic Development and Catalysts and before that the Vice President of Catalysts. Previously, he had roles in Fine Chemistry, led the Global Flame Retardants business, and headed the Bromine Businesses in Asia from 1995 to 1998.
Dr. David Anton heads up the technology side. He has more than 25 years of experience directing development of new technology solutions and production processes. Before joining Codexis, Dr. Anton was at DuPont, where he held a variety of senior research management positions across bioprocessing and biocatalysis. He led the process research, development and commercialisation of several products, including 1,3 propanediol (a chemical intermediate used in a variety of industrial applications ranging from airplane deicing fluids to textiles and carpet).